Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ovarian Cancer: Update Bulletin #1 [July 2018]

Product Code:
596201004
Publication Date:
July 2018
Format:
PDF
Price:
£910

Gain new KOL insights on the latest events happening in ovarian cancer, including: the US approval of Roche’s Avastin (bevacizumab) in combination with chemotherapy, followed by Avastin monotherapy, for the treatment of advanced (stage III or IV) ovarian cancer following initial surgical resection; the EU approval of Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) for the treatment of platinum-sensitive, relapsed or progressive, BRCA-mutated (germline and/or somatic) ovarian cancer; the expanded approval of AstraZeneca’s PARP inhibitor Lynparza (olaparib) in the EU to include the maintenance treatment of patients with platinum-sensitive, relapsed ovarian cancer, regardless of BRCA status; and the SOLO-1 trial of Lynparza as a first-line maintenance therapy for women with BRCA-mutated advanced ovarian cancer meeting its primary endpoint of progression-free survival (PFS).

Business Questions:

• How do KOLs react to the US approval of Avastin in combination with chemotherapy, followed by Avastin monotherapy, for the treatment of advanced ovarian cancer following initial surgical resection?
• In light of the recent US approval, how widely will Avastin in combination with chemotherapy be prescribed as a first-line regimen?
• What do KOLs consider to be the major advantages and drawbacks to first-line Avastin plus chemotherapy, followed by Avastin monotherapy?
• How do KOLs view the EU approval of Rubraca for the treatment of patients with platinum-sensitive, relapsed or progressive, BRCA-mutated ovarian cancer?
• What is the overall outlook for Rubracaas a treatment for recurrent disease?
• How do KOLs react to Lynparza’s expanded EU approval to include the maintenance treatment of platinum-sensitive, relapsed ovarian cancer regardless of BRCA-mutation status?
• How do Lynparza, Rubraca and Zejula compare in the relapsed maintenance setting, and how will oncologists choose between them?
• How do KOLs rate the significance of the SOLO-1 trial of Lynparza, in the first-line maintenance setting, meeting its primary endpoint of PFS?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved